Skip to main content
. 2018 Mar 13;8:4395. doi: 10.1038/s41598-018-22662-6

Figure 3.

Figure 3

Acetylation of C/EBP-α increases its stability and protein level by inhibiting ubiquitination. (A) CHX treatment leads to a time-dependent reduction in C/EBP-α as determined by Western blot analysis. (B) TSA and NAM treatment blocks the effect of CHX on C/EBP-α protein levels. (C) The ubiquitin proteasome inhibitor MG132 causes the accumulation of C/EBP-α protein. (D) The lysosomal proteasome inhibitor leupeptin had no effects on C/EBP-α protein. (E and F) Deacetylase inhibitors promote the acetylation of C/EBP-α but inhibit ubiquitination. *p < 0.05 and **p < 0.01 compared to no treatment group.